Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663793 · ClinicalTrials.gov registry record · Phase 1
ORAL T-6: Oral Androgens in Man-6
A Phase 1 study of Contraception and Hypogonadism, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00663793: Completed Phase 1 study of Contraception and Hypogonadism, sponsored by University of Washington.
NCT00663793 is a Phase 1 study of Contraception and Hypogonadism that has completed, run by University of Washington. The registered enrollment target is 16 participants, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00663793, a Phase 1 study of Contraception and Hypogonadism, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose a study to determine the single-dose pharmacokinetics of these two novel formulations of testosterone in normal men with experimentally induced hypogonadism.
Conditions Studied
Interventions
- DRUG Finasteride
- DRUG Testosterone
- DRUG Acyline
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT00663793 record still lists
NCT00663793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 454-participant average among 72 other Contraception trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Contraception appearing as the primary indexed condition, and to 3 interventions - of which Finasteride is the first listed.
NCT00663793 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00663793 about?
NCT00663793 is a clinical study titled "ORAL T-6: Oral Androgens in Man-6". We propose a study to determine the single-dose pharmacokinetics of these two novel formulations of testosterone in normal men with experimentally induced hypogonadism.
What is the current status of trial NCT00663793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-10. Estimated completion is 2009-06.
What conditions does trial NCT00663793 study?
This clinical trial studies the following conditions: Contraception, Hypogonadism.
What interventions are being tested in trial NCT00663793?
The interventions under investigation include: Finasteride (DRUG), Testosterone (DRUG), Acyline (DRUG).
Who is sponsoring clinical trial NCT00663793?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00663793 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00663793's enrollment target sits among peer trials
16 67th of 72 higher than 6 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
COMPLETED · Phase 1
-
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
COMPLETED · Phase 1
-
NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel
COMPLETED · Phase 1
-
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
COMPLETED · Phase 1
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia